33.81
-0.23 (-0.68%)
| Penutupan Terdahulu | 34.04 |
| Buka | 33.84 |
| Jumlah Dagangan | 1,705,371 |
| Purata Dagangan (3B) | 509,348 |
| Modal Pasaran | 936,904,640 |
| Harga / Jualan (P/S) | 411.22 |
| Harga / Buku (P/B) | 11.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -19.84 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.16% |
| Nisbah Semasa (MRQ) | 21.11 |
| Aliran Tunai Operasi (OCF TTM) | -108.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -65.95 M |
| Pulangan Atas Aset (ROA TTM) | -44.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | RAPT Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.17 |
|
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 99.41% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |